Liver disease · Not applicable
Tesamorelin: abdominal and liver fat in HIV
What was tested?
Tesamorelin versus placebo in antiretroviral-treated patients with HIV and abdominal fat accumulation. ↗
Registered primary question: Change in visceral adipose tissue and liver fat at six months. ↗
What the reviewed report found
Journal year 2014 · Article summary reviewed 2026-08-19
The reported treatment difference was -42 square centimeters for visceral adipose tissue and -2.9 percentage points for liver fat. The six-month glucose changes were not statistically significant.↗
Keep in context: The registry lists 54 enrolled; the paper describes 50 randomized and 48 treated. This small, single-center study measured fat changes rather than long-term clinical outcomes. ↗↗
Participants, design, limitations and sources
Registry snapshot
- Registry enrollment
- 54 · reported actual
- Registry status
- Completed
- Allocation and masking
- Randomized · Quadruple
- Design
- Parallel
- Eligible ages
- 18 Years to 65 Years
- Registry results
- Posted in this snapshot
Registry source ↗ · Updated 2017-10-30; retrieved 2026-09-20. Registry enrollment is not necessarily the analyzed sample in a publication. Posted registry results and published article results are separate.
Six-month visceral- and liver-fat trial
- Design in the report
- A double-blind, randomized, placebo-controlled preliminary trial assessed visceral adipose tissue, liver fat, and metabolic measures over six months.↗
- Participants in the report
- The single-center trial enrolled 50 antiretroviral-treated adults living with HIV and abdominal fat accumulation; 48 received study treatment.↗
- Limitations
- The preliminary study was small, single-center, and six months long; the authors stated that further study was needed to determine clinical importance and long-term consequences.↗
This reading covers the article abstract and record metadata. Read its preserved Human Evidence Review →
How the study identity and sources were checked
Study context checked 2026-09-20. Existing article summaries keep their original review dates. This is a selected study reading, not a complete literature or full-text appraisal.
Registry
Effects of Growth Hormone Releasing Hormone in HIV ↗
Protocol identifier: 2007p-000638. Sponsor: Massachusetts General Hospital.
Retrieved 2026-09-20; SHA-256 b996f043d627ecf369e566b4310ec94ae9593dd87ac8e98ebdf8c25c73535ee7.
PMID 25038357
Exact trial identity is declared in PubMed’s ClinicalTrials.gov databank field. The registry independently labels this reference RESULT. These source labels do not establish that every result in a paper applies to this trial.
Identity metadata retrieved 2026-09-20. EFetch batch XML; locate MedlineCitation/PMID 25038357. SHA-256 b9b2737876819a52052ecd9dc7208be1ad5712f7a133c5c13d04f6663f02d118.
Scientific summary uses the original 2026-08-19 source snapshot: SHA-256 c2d1ad86512b5f64e032d05b54059a7cf624edb143d01fffb7b6ba757962ad1d.